Hemogenyx Pharmaceuticals Plc

LSE:HEMO Voorraadrapport

Marktkapitalisatie: UK£16.1m

Hemogenyx Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Vladislav Sandler

Algemeen directeur

UK£397.0k

Totale compensatie

Percentage CEO-salaris98.0%
Dienstverband CEO10.9yrs
Eigendom CEO3.1%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur7.1yrs

Recente managementupdates

Recent updates

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Aug 21
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

May 04
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Jan 06
We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Oct 09
Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Analyse CEO-vergoeding

Hoe is Vladislav Sandler's beloning veranderd ten opzichte van Hemogenyx Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-UK£5m

Mar 31 2024n/an/a

-UK£6m

Dec 31 2023UK£397kUK£389k

-UK£7m

Sep 30 2023n/an/a

-UK£7m

Jun 30 2023n/an/a

-UK£7m

Mar 31 2023n/an/a

-UK£6m

Dec 31 2022UK£282kUK£276k

-UK£4m

Sep 30 2022n/an/a

-UK£3m

Jun 30 2022n/an/a

-UK£3m

Mar 31 2022n/an/a

-UK£4m

Dec 31 2021UK£213kUK£206k

-UK£5m

Sep 30 2021n/an/a

-UK£5m

Jun 30 2021n/an/a

-UK£5m

Mar 31 2021n/an/a

-UK£3m

Dec 31 2020UK£205kUK£200k

-UK£2m

Sep 30 2020n/an/a

-UK£2m

Jun 30 2020n/an/a

-UK£2m

Mar 31 2020n/an/a

-UK£2m

Dec 31 2019UK£149kUK£145k

-UK£1m

Sep 30 2019n/an/a

-UK£2m

Jun 30 2019n/an/a

-UK£2m

Mar 31 2019n/an/a

-UK£2m

Dec 31 2018UK£98kUK£94k

-UK£2m

Sep 30 2018n/an/a

-UK£2m

Jun 30 2018n/an/a

-UK£3m

Mar 31 2018n/an/a

-UK£3m

Dec 31 2017UK£79kUK£79k

-UK£2m

Compensatie versus markt: De totale vergoeding ($USD 497.46K ) Vladislav } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.22K ).

Compensatie versus inkomsten: De vergoeding van Vladislav is gestegen terwijl het bedrijf verliesgevend is.

CEO

Vladislav Sandler (59 yo)

10.9yrs

Tenure

UK£397,000

Compensatie

Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Vladislav Sandler
Co-Founder7.1yrsUK£397.00k3.1%
£ 498.5k
Alexis Sandler
Independent Co-Founder & Non-Executive Director7.1yrsUK£60.00k5.6%
£ 901.1k
Koen Van Besien
Clinical Advisor & Medical Directorno datageen gegevensgeen gegevens
H. Shepard
Member of Scientific Advisory Board6.7yrsgeen gegevensgeen gegevens
Peter Redmond
Independent Non-Executive Director9.3yrsUK£50.00k0.42%
£ 67.2k
Marc Feldmann
Independent Chairman & Chairman of Advisory Board7.2yrsUK£15.00kgeen gegevens

7.1yrs

Gemiddelde duur

74yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HEMO wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.1 jaar).